33 -7 (93) 2026 - Musaeva N.B., Babadjanova Sh.A. - REVMATOID ARTRITNING ERTA BOSQICHLARIDA ENDOTELIAL DISFUNKSIYA VA GEMOSTAZ KO‘RSATKICHLARINING KLINIK-LABORATOR AHAMIYATI

REVMATOID ARTRITNING ERTA BOSQICHLARIDA ENDOTELIAL DISFUNKSIYA VA GEMOSTAZ KO‘RSATKICHLARINING KLINIK-LABORATOR AHAMIYATI

Musaeva N.B., Babadjanova Sh.A. - Toshkent Davlat Tibbiyot Universiteti

Rezyume

Dolzarbligi. Revmatoid artrit surunkali autoimmun yallig‘lanish kasalligi bo‘lib, bo‘g‘im destruksiyasi bilan bir qatorda endotelial disfunksiya, mikrosirkulyator buzilishlar va gemostaz tizimidagi faollashuv bilan kechadi [1–4]. Maqsad. Revmatoid artritning juda erta va erta bosqichlarida endotelial disfunksiya hamda gemostaz ko‘rsatkichlarining klinik-laborator ahamiyatini baholash. Material va usullar. Tadqiqotga revmatoid artrit bilan og‘rigan 85 nafar bemor va 30 nafar amaliy sog‘lom shaxsdan iborat nazorat guruhi jalb qilindi. Bemorlar juda erta revmatoid artrit (n=32) va erta revmatoid artrit (n=53) guruhlariga ajratildi. D-dimer, antitrombin III, fon Villebrand omili, endotelin-1 va sICAM-1 ko‘rsatkichlari baholandi. Natijalar. D-dimer nazorat guruhida 210±60 ng/ml, juda erta RA guruhida 420±110 ng/ml, erta RA guruhida esa 680±160 ng/ml ni tashkil etdi. Antitrombin III faolligi 102±6% dan mos ravishda 94±7% va 88±8% gacha pasaydi. Fon Villebrand omili, endotelin-1 va sICAM-1 ko‘rsatkichlari har ikkala RA guruhida nazoratga nisbatan statistik ishonchli oshdi. Xulosa. RAning erta bosqichlaridayoq endotelial disfunksiya va gipergemostaz shakllanadi. D-dimer, antitrombin III, fon Villebrand omili, endotelin-1 va sICAM-1 ko‘rsatkichlarini kompleks baholash trombogen xavfni erta aniqlashda muhim ahamiyatga ega.

Kalit so‘zlar: revmatoid artrit, endotelial disfunksiya, gemostaz, D-dimer, antitrombin III, endotelin-1, sICAM-1, fon Villebrand omili.

First page

230

Last page

233

For citation:Musaeva N.B., Babadjanova Sh.A. - REVMATOID ARTRITNING ERTA BOSQICHLARIDA ENDOTELIAL DISFUNKSIYA VA GEMOSTAZ KO‘RSATKICHLARINING KLINIK-LABORATOR AHAMIYATI//New Day in Medicine 7(93)2026 230-233 https://newdayworldmedicine.com/en/new_day_medicine/7-93-2026

List of References

1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-1588. doi: 10.1136/ard.2010.138461.
2. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi: 10.1136/ard-2022-223356.
3. Yang XZ, Chang Y, Wei W. Endothelial dysfunction and inflammation: immunity in rheumatoid arthritis. Mediators Inflamm. 2016;2016:6813016. doi: 10.1155/2016/6813016.
4. Anyfanti P, Gavriilaki E, Douma S, Gkaliagkousi E. Endothelial dysfunction in patients with rheumatoid arthritis: the role of hypertension. Curr Hypertens Rep. 2020;22(8):56. doi: 10.1007/s11906-020-01066-8.
5. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4(6):1186-1193. doi: 10.1111/j.1538-7836.2006.01949.x.
6. Manz XD, Doddaballapur A, Hynes RO, Wagner DD. Regulation of VWF in inflammatory and thrombotic diseases. Arterioscler Thromb Vasc Biol. 2022;42(11):1307-1320. doi: 10.1161/ATVBAHA.122.318179.
7. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, et al. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis. 2002;61(9):804-809. doi: 10.1136/ard.61.9.804.
8. Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study. Ann Rheum Dis. 2021;80(2):169-175. doi: 10.1136/annrheumdis-2020-218419.
9. Hu LJ, Ji B, Fan HX. Venous thromboembolism risk in rheumatoid arthritis patients: a systematic review and updated meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(22):7005-7013. doi: 10.26355/eurrev_202111_27206.
10. Fazal ZA, Stavropoulos-Kalinoglou A, Metsios GS, Kitas GD. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Egypt Rheumatol Rehabil. 2024;51:20. doi: 10.1186/s43166-024-00257-7.

    file

    download